سعر فيم 7-75 ميكروجرام 4 لصقات عبر الجلد 75 مكجم/24 hours 2022

Estradiol transdermal patch releasing 75 micrograms of estradiol per 24 hours, applied once weekly; pack of 4 patches.

• Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women.Population: Postmenopausal womenemc (medicines.org.uk)
• Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicines approved for osteoporosis prevention.Population: Postmenopausal women at high fracture riskemc (medicines.org.uk)
• Treatment of moderate to severe vasomotor symptoms and of vulvar and vaginal atrophy due to menopause; hypoestrogenism; prevention of postmenopausal osteoporosis (US Climara label).Population: Postmenopausal womenDailyMed (U.S. National Library of Medicine)

• Most frequent (>10%): application site reactions (pruritus, erythema, eczema, urticaria, oedema, pigmentation changes), usually mild and resolving 2-3 days after patch removal. Common: headache, nausea, abdominal pain, breast disorders, among others.International label, same formulation · emc (medicines.org.uk)

• Known, past or suspected breast cancer; known or suspected oestrogen-dependent malignant tumours; undiagnosed genital bleeding; untreated endometrial hyperplasia; previous or current venous thromboembolism; known thrombophilic disorders; active or recent arterial thromboembolic disease; acute or past liver disease with abnormal liver tests; porphyria; hypersensitivity to the active substance or excipients.International label, same formulation · emc (medicines.org.uk)

• In women with a uterus, unopposed oestrogen increases the risk of endometrial hyperplasia and carcinoma; a progestogen must be added cyclically for at least 12 days per cycle. For patches above 50 micrograms/day the endometrial safety of added progestogens has not been demonstrated.International label, same formulation · emc (medicines.org.uk)
• HRT is associated with a 1.3-3 fold risk of venous thromboembolism, highest in the first year; consider stopping HRT 4-6 weeks before elective surgery with prolonged immobilisation.International label, same formulation · emc (medicines.org.uk)
• HRT should be started only for symptoms that adversely affect quality of life, using the lowest effective dose for the shortest duration, with a benefit-risk review at least annually; breast cancer and ovarian cancer risks are slightly increased.International label, same formulation · emc (medicines.org.uk)

• Enzyme inducers (phenobarbital, phenytoin, carbamazepine, rifampicin, rifabutin, nevirapine, efavirenz, St John's wort; ritonavir/nelfinavir)May increase oestrogen metabolism, reducing effect and changing the bleeding profile; transdermal route avoids first-pass and may be less affected.emc (medicines.org.uk)
• LamotrigineOestrogen-containing hormone products significantly decreased lamotrigine plasma concentrations (induction of glucuronidation), which may reduce seizure control.emc (medicines.org.uk)

• Not indicated during pregnancy; if pregnancy occurs treatment should be withdrawn immediately. Most epidemiological studies of inadvertent fetal exposure to oestrogens indicate no teratogenic or fetotoxic effects.International label, same formulation · emc (medicines.org.uk)
• Not indicated during lactation.International label, same formulation · emc (medicines.org.uk)

• Estradiol: Synthetic 17-beta estradiol, chemically and biologically identical to endogenous estradiol, replaces the loss of ovarian estrogen production after menopause (UK FemSeven SmPC 5.1).